NeuroBo Pharma Files Routine 8-K on Jan 8 Event
Ticker: MTVA · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**NRBO filed a standard 8-K, no big news here.**
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024. This filing is a routine update to the SEC, indicating no major new financial or operational news. For investors, this means there's no immediate new information that would drastically alter the stock's valuation or outlook, suggesting a period of stability or continued focus on existing developments.
Why It Matters
This filing is a standard procedural update, indicating no significant new developments that would immediately impact NeuroBo Pharmaceuticals' stock price or business operations. It's important for investors to know when a filing is routine versus when it signals a major event.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not disclose any new risks or material changes to the company's operations or financial health.
Analyst Insight
A smart investor would note this as a non-event and continue to monitor for more substantive filings, such as those related to clinical trial results, financing, or strategic partnerships, which would have a greater impact on the stock.
Key Numbers
- $0.001 — Par Value per Share (The par value of NeuroBo Pharmaceuticals, Inc.'s Common Stock.)
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of the earliest event reported
- January 9, 2024 (date) — date the 8-K was filed
- Nasdaq Stock Market LLC (company) — exchange where NeuroBo's common stock is registered
- NRBO (company) — trading symbol for NeuroBo Pharmaceuticals, Inc.
- $0.001 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- NeuroBo Pharmaceuticals will continue to file routine administrative 8-Ks without significant new disclosures in the near term. (NeuroBo Pharmaceuticals, Inc.) — high confidence, target: Q1 2024
FAQ
What is the purpose of this 8-K filing by NeuroBo Pharmaceuticals, Inc.?
This 8-K filing is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting an event that occurred on January 8, 2024. It falls under 'Other Events' and 'Financial Statements and Exhibits', but the content provided does not detail specific new material events, suggesting it's a routine update.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024.
What is the trading symbol and the exchange where NeuroBo Pharmaceuticals, Inc.'s common stock is registered?
NeuroBo Pharmaceuticals, Inc.'s common stock trades under the symbol 'NRBO' and is registered on The Nasdaq Stock Market LLC.
What is the par value of NeuroBo Pharmaceuticals, Inc.'s common stock?
The par value of NeuroBo Pharmaceuticals, Inc.'s common stock is $0.001 per share.
What is the business address and phone number of NeuroBo Pharmaceuticals, Inc.?
The business address of NeuroBo Pharmaceuticals, Inc. is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138, and their telephone number is (857) 702-9600.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-09 08:45:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
- $1.00 — aintain a closing bid price of at least $1.00 per share, and that the Company satisfi
Filing Documents
- nrbo-20240108x8k.htm (8-K) — 41KB
- nrbo-20240108xex99d1.htm (EX-99.1) — 10KB
- nrbo-20240108x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240108xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-000143.txt ( ) — 219KB
- nrbo-20240108.xsd (EX-101.SCH) — 3KB
- nrbo-20240108_lab.xml (EX-101.LAB) — 15KB
- nrbo-20240108_pre.xml (EX-101.PRE) — 9KB
- nrbo-20240108x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 8, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company" ) received formal notification (the "Notification" ) from The Nasdaq Stock Market LLC ( "Nasdaq" ) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to maintain a closing bid price of at least $1.00 per share, and that the Company satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result of the determination, the listing matter is now closed. A press release issued by the Company on January 9, 2024 regarding the Notification is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated January 9, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: January 9, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer